Currently, the Food and Drug Administration (FDA) has officially approved JAK/STAT inhibitors for the management of various pathological conditions, including MPN, graft-versus-host disease, pancreatic cancer, rheumatoid arthritis, and coronavirus disease 2019 [96]. Here, SOAT1 is linked to myeloproliferative neoplasm.